Immunoadjuvant activity of a liposomal IL-6 formulation.
暂无分享,去创建一个
[1] M. Lenardo. lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.
[2] A. Duits,et al. Selective Enhancement of Leu Cam Expression by Interleukin 6 during Differentiation of Human Promonocytic U937 Cells , 1991, Scandinavian journal of immunology.
[3] J. Playfair,et al. Conjugation of interferon-gamma to antigen enhances its adjuvanticity. , 1990, Immunology.
[4] S. Rosenberg,et al. Antitumor activity of recombinant interleukin 6 in mice , 1990, The Journal of experimental medicine.
[5] G. Gregoriadis,et al. Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators. , 1989, Immunology.
[6] T. Kishimoto,et al. The biology of interleukin-6. , 1989, Blood.
[7] Toshio Hirano,et al. Genes coding for RNA polymerase β subunit in bacteria , 1988 .
[8] T. Hirano,et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. , 1988 .
[9] T. Hirano,et al. Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. , 1988, Journal of immunology.
[10] L. Aarden,et al. Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.
[11] A Muraguchi,et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells , 1988, The Journal of experimental medicine.
[12] L. Aarden,et al. Molecular cloning and expression of hybridoma growth factor in Escherichia coli. , 1987, Journal of immunology.
[13] G. Gregoriadis,et al. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics. , 1987, Immunology.
[14] F. Szoka,et al. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[15] G. Gregoriadis. Immunological adjuvants: a role for liposomes. , 1990, Immunology today.
[16] F. Audibert,et al. Immunoadjuvants and analogs of immunomodulatory bacterial structures. , 1989, Current opinion in immunology.
[17] D. Gerlier,et al. Impairment of immunogenicity by antigen presentation in liposomes made from dimyristoylphosphatidyl‐ethanolamine linked to the secretion of prostaglandins by macrophages , 1987, European journal of immunology.
[18] J H Senior,et al. Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.